scholarly journals Association of gene variants in the transforming growth factor beta signalling pathways with invasive breast cancer risk

2006 ◽  
Vol 8 (S2) ◽  
Author(s):  
S Scollen ◽  
AM Dunning ◽  
R Hesketh ◽  
JC Metcalfe
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Invasive Breast Cancer ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Signalling Pathways ◽  
Gene Variants ◽  
Growth Factor Beta

The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk

2003 ◽  
Vol 201 (2) ◽  
pp. 181-184 ◽  
Author(s):  
Peter Krippl ◽  
Uwe Langsenlehner ◽  
Wilfried Renner ◽  
Babak Yazdani-Biuki ◽  
Gerald Wolf ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Growth Factor Beta

scholarly journals Association of gene variants in the TGF-beta signalling pathways with invasive breast cancer risk

2008 ◽  
Vol 10 (S2) ◽  
Author(s):  
S Scollen ◽  
AM Dunning ◽  
AC Bradshaw ◽  
R Hesketh ◽  
JC Metcalfe
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Invasive Breast Cancer ◽  
Signalling Pathways ◽  
Gene Variants ◽  
Tgf Beta

Transforming Growth Factor Beta 1 Serum Levels in Patients with Preinvasive and Invasive Lesions of the Breast

2004 ◽  
Vol 19 (3) ◽  
pp. 236-239 ◽  
Author(s):  
A. Lebrecht ◽  
C. Grimm ◽  
G. Euller ◽  
E. Ludwig ◽  
E. Ulbrich ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Serum Levels ◽  
Breast Carcinogenesis ◽  
Receptor Status ◽  
Healthy Women ◽  
Growth Factor Beta ◽  
Tgf Β1

Transforming growth factor beta (TGF-β)1 is thought to be involved in breast carcinogenesis. TGF-β1 acts in an antiproliferative manner in the early stages of breast carcinogenesis, but promotes tumor progression and metastases in the advanced stages of the disease. No data have been published on serum TGF-β1 in breast cancer. We investigated TGF-β1 serum levels in patients with breast cancer (n=135), ductal carcinoma in situ (DCIS) I to III (n=67) or fibroadenoma (n=35), and in healthy women (n=40) to determine its value as a differentiation marker between malignant, pre-invasive and benign diseases and as a predictive marker for metastatic spread. Median (range) TGF-β1 serum levels in patients with breast cancer, DCIS I-III or benign breast lesions and in healthy women were 48.8 (18–82.4) pg/mL, 45.3 (26.9–58.3) pg/mL, 47.2 (17.2–80.5) pg/mL and 51.6 (30.9–65.1) pg/mL, respectively (p=0.2). In breast cancer patients TGF-β1 serum levels showed no statistically significant correlation with tumor stage, lymph node involvement, histological grade, estrogen receptor status and progesterone receptor status. Our data fail to indicate any correlation between serum TGF-β1 levels and clinicopathological parameters of breast diseases. Serum TGF-β1 levels do not provide clinical information in addition to established tumor markers.

scholarly journals Genetic Variations in the Transforming Growth Factor Beta Pathway as Predictors of Bladder Cancer Risk

PLoS ONE ◽  
2012 ◽  
Vol 7 (12) ◽  
pp. e51758 ◽  
Author(s):  
Hua Wei ◽  
Ashish M. Kamat ◽  
Saad Aldousari ◽  
Yuanqing Ye ◽  
Maosheng Huang ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Growth Factor ◽  
Cancer Risk ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Genetic Variations ◽  
Bladder Cancer Risk ◽  
Growth Factor Beta
Sign in / Sign up

Export Citation Format

Share Document